| Identification | Back Directory | [Name]
vinaxanthone | [CAS]
133293-89-7 | [Synonyms]
vinaxanthone
9H-Xanthene-1-carboxylic acid, 5,7-diacetyl-6-(5-carboxy-6,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl)-2,3-dihydroxy-9-oxo- | [Molecular Formula]
C28H16O14 | [MOL File]
133293-89-7.mol | [Molecular Weight]
576.42 |
| Hazard Information | Back Directory | [Uses]
Vinaxanthone is used in the pharmaceutical composition containing xanthone compound SM-?345431 for treating cerebral infarction. | [in vivo]
Vinaxanthone (SM-345431) (0.1 mg/mL, Subconjunctival injections, every 2 days, 3 weeks) accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model[4].
Vinaxanthone (SEMA3A-I) (20 μg, i.p.) protects from Doxorubicin (HY-15142A)-induced podocyte injury through an anti-apoptosis mechanism in mouse model of Doxorubicin (HY-15142A)-induced podocytopathy[5].
| Animal Model: | murine corneal transplantation model[4] | | Dosage: | 0.1 mg/mL | | Administration: | Subconjunctival injections, every 2 days, 3 weeks | | Result: | Showed significantly higher nerve growth.
Improved the corneal sensitivity.
|
| Animal Model: | mouse model of Doxorubicin (10 mg/kg)-induced podocytopathy[5] | | Dosage: | 20 μg | | Administration: | Intraperitoneal injection (i.p.), every day | | Result: | Improved the expression of nephrin.
Reduced podocytopathy and tubular casts.
Detected rarely TUNEL-positive cells in the Dox + Vinaxanthone group.
Had fewer p-c-Jun-positive cells in the Dox + Vinaxanthone group.
|
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
CHEMICAL LAND21
|
| Tel: |
82- 2 -783 - 8063 |
| Website: |
www.chemicalland21.com |
|